Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease

• Published in: Science translational medicine Vol. 11; no. 507
• Main Authors: Ewers, Michael, Franzmeier, Nicolai, Suárez-Calvet, Marc, Morenas-Rodriguez, Estrella, Caballero, Miguel Angel Araque, Kleinberger, Gernot, Piccio, Laura, Cruchaga, Carlos, Deming, Yuetiva, Dichgans, Martin, Trojanowski, John Q, Shaw, Leslie M, Weiner, Michael W, Haass, Christian
• Format: Journal Article
• Language: English
• Published: United States 28.08.2019
• Subjects: Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - physiopathology; Amyloid beta-Peptides - cerebrospinal fluid; Cognition - physiology; Cross-Sectional Studies; Humans; Membrane Glycoproteins - cerebrospinal fluid; Membrane Glycoproteins - physiology; Neuropsychological Tests; Receptors, Immunologic - physiology; tau Proteins - cerebrospinal fluid
• ISSN: 1946-6242
• DOI: 10.1126/scitranslmed.aav6221

Loss of function of TREM2, a key receptor selectively expressed by microglia in the brain, contributes to the development of Alzheimer's disease (AD). We therefore examined whether soluble TREM2 (sTREM2) concentrations in cerebrospinal fluid (CSF) were associated with reduced rates of cognitive decline and clinical progression in subjects with AD or mild cognitive impairment (MCI). We measured sTREM2 in CSF samples from 385 elderly subjects, including cognitively normal controls, individuals with MCI, and subjects with AD dementia (follow-up period: mean, 4 years; range 1.5 to 11.5 years). In subjects with AD defined by evidence of CSF Aβ (amyloid β-peptide 1 to 42; A+) and CSF p-tau (tau phosphorylated on amino acid residue 181; T+), higher sTREM2 concentrations in CSF at baseline were associated with attenuated decline in memory and cognition. When analyzed in clinical subgroups, an association between higher CSF sTREM2 concentrations and subsequent reduced memory decline was consistently observed in individuals with MCI or AD dementia, who were positive for CSF Aβ and CSF p-tau (A+T+). Regarding clinical progression, a higher ratio of CSF sTREM2 to CSF p-tau concentrations predicted slower conversion from cognitively normal to symptomatic stages or from MCI to AD dementia in the subjects who were positive for CSF Aβ and CSF p-tau These results suggest that sTREM2 is associated with attenuated cognitive and clinical decline, a finding with important implications for future clinical trials targeting the innate immune response in AD.